April 4, 2025

Honorable David S. Doty Sr. U.S. District Judge, District of Minnesota United States District Court 14W U.S. Court House 300 South Fourth Street Minneapolis, MN 55415

Re: Pharmaceutical Research and Manufacturers of America v. Chakolis

Court File Number: 20-CV-1497-DSD-DTS

## Dear Judge Doty:

Defendants write to advise the Court of supplemental authority relating to their pending motion to dismiss. The Court in *Minnesota by Ellison v. Sanofi-Aventis U.S. LLC*, No. 2:18-cv-14999-BRM-RLS (D.N.J.) approved a settlement agreement between the State and Novo Nordisk Inc. on March 25 (ECF 204) and dismissed the entire matter on April 1 (ECF 207). Under the agreement, Novo Nordisk must make its insulin products available for \$35 per month or less to cash-paying customers, as defined therein, and continue offering free insulin to certain Minnesota residents, among other terms. Citation to the March 25 order in *Minnesota by Ellison v. Sanofi-Aventis US LLC*, supplements the arguments presented on pages 4 and 16 of Defendants' memorandum supporting dismissal (ECF 155) and on page 8 of Defendants' reply memorandum (ECF 160).

Respectfully submitted,

SARAH L. KRANS

**Assistant Attorney General** 

Sarah Kraws

(651) 757-1273 (Voice)

(651) 297-1235 (Fax)

sarah.krans@ag.state.mn.us

Attorney for Defendants